| Level 1 | Strong evidence |
| | Recommended drug and dose |
| | Pregabalin, 300–600 mg/d | |
| Level 2 | Moderate evidence |
| | Recommended drug and dose | Not recommended |
| | Gabapentin, 900–3,600 mg/d | Oxcarbazepine |
| | Sodium valproate, 500–1,200 mg/d | Lamotrigine |
| | Venlafaxine, 75–225 mg/d | Lacosamide |
| | Duloxetine, 60–120 mg/d | Clonidine |
| | Amitriptyline, 25–100 mg/d | Pentoxifylline |
| | Dextromethorphan, 400 mg/d | Mexiletine |
| | Morphine sulphate, titrated to 120 mg/d | Magnetic field treatment |
| | Tramadol, 210 mg/d | Low-intensity laser therapy |
| | Oxycodone, mean 37 mg/d, max 120 mg/d | Reiki therapy |
| | Capsaicin, 0.075% QID | |
| | Isosorbide dinitrate spray | |
| | Electrical stimulation, percutaneous nerve stimulation 3–4 weeks | |
| Level 3 | Weak evidence |
| | Venlafaxine | |
| | Gabapentin | |
| | Lidoderm patch | |
| Level 4 | Insufficient evidence |
| | Topiramate | Fluoxetine |
| | Desipramine | Combination of nortriptyline and fluphenazine |
| | Imipramine | Vitamins |
| | β-lipoic acid | Combination of amitriptyline with electrotherapy |
